134 related articles for article (PubMed ID: 35235342)
1. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.
Sandberg ML; Wang X; Martin AD; Nampe DP; Gabrelow GB; Li CZ; McElvain ME; Lee WH; Shafaattalab S; Martire S; Fisher FA; Ando Y; Liu E; Ju D; Wong LM; Xu H; Kamb A
Sci Transl Med; 2022 Mar; 14(634):eabm0306. PubMed ID: 35235342
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
[TBL] [Abstract][Full Text] [Related]
3. Robust
Manry D; Bolanos K; DiAndreth B; Mock JY; Kamb A
Front Immunol; 2022; 13():826747. PubMed ID: 35359952
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
5. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
[TBL] [Abstract][Full Text] [Related]
7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
8. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
9. A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.
Wang X; Wong LM; McElvain ME; Martire S; Lee WH; Li CZ; Fisher FA; Maheshwari RL; Wu ML; Imun MC; Murad R; Toledo Warshaviak D; Yin J; Kamb A; Xu H
Toxicol Appl Pharmacol; 2022 Feb; 437():115894. PubMed ID: 35085592
[TBL] [Abstract][Full Text] [Related]
10. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.
Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J
Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666
[TBL] [Abstract][Full Text] [Related]
11. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Parkhurst MR; Joo J; Riley JP; Yu Z; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2009 Jan; 15(1):169-80. PubMed ID: 19118044
[TBL] [Abstract][Full Text] [Related]
12. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E; Toutirais O; Tougeron D; Drouet A; Le Gallo M; Desille M; Cabillic F; de La Pintière CT; Iero M; Rivoltini L; Baert-Desurmont S; Leprince J; Vaudry H; Sesboué R; Frébourg T; Latouche JB; Catros V
J Immunother; 2010 May; 33(4):402-13. PubMed ID: 20386466
[TBL] [Abstract][Full Text] [Related]
13. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L
Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685
[TBL] [Abstract][Full Text] [Related]
14. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
Tsang KY; Zaremba S; Nieroda CA; Zhu MZ; Hamilton JM; Schlom J
J Natl Cancer Inst; 1995 Jul; 87(13):982-90. PubMed ID: 7629885
[TBL] [Abstract][Full Text] [Related]
15. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.
Wu Y; Wan T; Zhou X; Wang B; Yang F; Li N; Chen G; Dai S; Liu S; Zhang M; Cao X
Cancer Res; 2005 Jun; 65(11):4947-54. PubMed ID: 15930317
[TBL] [Abstract][Full Text] [Related]
16. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.
Blat D; Zigmond E; Alteber Z; Waks T; Eshhar Z
Mol Ther; 2014 May; 22(5):1018-28. PubMed ID: 24686242
[TBL] [Abstract][Full Text] [Related]
17. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
[TBL] [Abstract][Full Text] [Related]
18. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma.
Guadagni F; Witt PL; Robbins PF; Schlom J; Greiner JW
Cancer Res; 1990 Oct; 50(19):6248-55. PubMed ID: 2119252
[TBL] [Abstract][Full Text] [Related]
19. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
[TBL] [Abstract][Full Text] [Related]
20. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]